Pfizer (PFE -0.3%) CEO Albert Bourla confirms that results from its large-scale late-stage study of COVID-19 vaccine candidate BNT162b2 will be available next month. If positive, it will immediately file for emergency use authorization in the U.S.
As of yesterday, 23K people have been enrolled in the 30K-subject trial.
Related ticker: BioNTech (BNTX -1.7%)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.